Friday, October 31, 2014
YOLO COUNTY NEWS
99 CENTS

UCD participates in research on macular degeneration

By
May 3, 2011 |

UC Davis ophthalmologists are among the group of national researchers reporting results from the first year of a two-year clinical trial that showed Avastin, a drug approved to treat some cancers that is commonly used off-label to treat age-related macular degeneration, is as effective as the Food and Drug Administration-approved drug Lucentis for treating AMD.

The report, from the Comparison of AMD Treatments Trials, published online in the New England Journal of Medicine on Sunday, May 1. The study is funded by the National Eye Institute, a part of the National Institutes of Health.

“It was important for UC Davis to be a part of this study,” said Susanna Park, professor of ophthalmology at the UCD Eye Center and the principal investigator for the UCD CATT study. “Currently, our patients are given many options for treating wet macular degeneration without solid data on the relative efficacy of those options. By testing two drugs and two dosing regimens side by side, the results of this study will allow us to base our treatment recommendations on solid scientific data.”

Age-related macular degeneration is the leading cause of vision loss and blindness in older Americans. In its advanced stages, the wet form of the disease spurs the growth of abnormal blood vessels, which leak fluid and blood into the macula and obscure vision. The macula is the central portion of the retina that allows individuals to look straight ahead and to perceive fine visual detail. Accumulation of fluid and blood damages the macula, causing loss of central vision. AMD can severely impede mobility and independence. Many patients are unable to drive, read, recognize faces or perform tasks that require hand-eye coordination.

“Over 250,000 patients are treated each year for AMD, and a substantial number of them receive Avastin. Given the lack of efficacy data regarding Avastin for AMD treatment, the NEI had an obligation to patients and clinicians to conduct this study,” said Paul A. Sieving, director of the NEI.

Ruth Rippon, a Sacramento artist and participant in the UCD CATT study, was referred to UCD retinal specialists because her eyesight was continually declining, something she noticed while reading the newspaper each day. Diagnosed with AMD, she began treatments through the study to save and potentially improve her sight. She does not know which medication she received. However, her vision is better.

“I can see more than just the headlines now,” Rippon said. “I’m really glad that the study helped me and that it could also help others with the disease.”

Genentech, the maker of both drugs, originally developed Avastin to prevent blood-vessel growth that enables cancerous tumors to develop and spread. In 2004, the FDA approved Avastin for the systemic treatment of metastatic colon cancer. Genentech later developed Lucentis, derived from a protein similar to Avastin, specifically for injection in the eye to block blood-vessel growth in macular degeneration.

In 2005, two Genentech-sponsored clinical trials established Lucentis as highly effective for the treatment of wet AMD. During the year between the announcement of the trial results and the release of Lucentis, ophthalmologists began injecting AMD patients with low doses of Avastin, due to its similarity to Lucentis and its availability. The FDA has not licensed Avastin for the treatment of AMD.

Numerous physicians noted a beneficial treatment effect and Avastin’s use grew rapidly despite the lack of data on safety, efficacy and dosing from randomized clinical trials to support its use. Ophthalmologists used Avastin primarily as needed, or pro re nata, when there was evidence of active disease. The FDA approved Lucentis in 2006. However, most clinicians adopted as-needed dosing for Lucentis, which was a departure from FDA-approved labeling and the monthly dosing schedule evaluated in the Genentech-sponsored clinical trials. It was not known if as-needed dosing would produce the same long-term vision benefits that were achieved with monthly administration.

NEI launched CATT in 2008 to compare Lucentis and Avastin for treating wet AMD. The study has now reported results for 1,185 patients treated at 43 clinical centers in the United States. At UCD, 23 patients are participating in the study. Patients were randomly assigned and treated with one of four regimens for a year. They received Lucentis monthly or as needed, or Avastin monthly or as needed. Enrollment criteria required that study participants had active disease.

Patients in the monthly dosing groups received an initial treatment and then had an injection every 28 days. Patients in the as-needed groups received an initial treatment and were then examined every 28 days to determine medical need for additional treatment. As-needed groups received subsequent treatment when there were signs of disease activity, such as fluid in the retina. Ophthalmologists involved in patient care did not know which study drug a patient was getting, to make sure that the data was not affected by how anyone felt about the treatment.

Change in visual acuity served as the primary outcome measure for CATT. Thus far, visual-acuity improvement was virtually identical (within one letter difference on an eye chart) for either drug when given monthly. In addition, no difference was found in the percentage of patients who had an important gain or loss in visual function. Also, when each drug was given on an as-needed schedule, there also was no difference (within one letter) between drugs. As-needed dosing required four to five fewer injections per year than monthly treatment. Visual gains were about two letters less with as-needed than with monthly treatment, but overall visual results were still excellent.

“In addition to the primary finding of equivalence between Lucentis and Avastin for visual acuity, CATT also demonstrates that as-needed dosing is a viable treatment option for either of these drugs,” said Daniel F. Martin, study chair for CATT and chairman of the Cole Eye Institute at the Cleveland Clinic. “Substantial visual acuity gains may be accomplished with a lower treatment burden.”

Adverse events indicate development or worsening of a medical condition. They may or may not be causally associated with the clinical trial treatment, but they are always monitored and reported in any clinical trial. The median age of patients in CATT was over 80 years, and a high rate of hospitalizations might be anticipated as a result of chronic or acute medical conditions more common to older populations.

Serious adverse events (primarily hospitalizations) occurred at a 24 percent rate for patients receiving Avastin and a 19 percent rate for patients receiving Lucentis. These events were distributed across many different conditions, most of which were not associated with Avastin in cancer clinical trials, where the drug was administered at 500 times the dose used for AMD. The number of deaths, heart attacks and strokes were low and similar for both drugs during the study. CATT was not capable of determining whether there is an association between a particular adverse event and treatment. Differences in serious adverse event rates require further study.

CATT investigators will continue to follow patients through a second year of treatment. These additional data will provide information on longer-term effects of the drugs on vision and safety.

The FDA has not evaluated data from the CATT trial.

Find more information about this clinical trial (NCT00593450) at http://www.clinicaltrials.gov.

The National Eye Institute, part of the National Institutes of Health, leads the federal government’s research on the visual system and eye diseases. The institute supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit http://www.nei.nih.gov.

The UC Davis Eye Center is a leader in collaborative vision research that is leading to cures for blinding eye disease and in providing state-of-the-art, world-class eye care. For more information, visit http://www.ucdmc.ucdavis.edu/eyecenter.

Comments

comments

Special to The Enterprise

  • Recent Posts

  • Enter your email address to subscribe to this newspaper and receive notifications of new articles by email.

  • .

    News

     
    State superintendent makes campaign stop in Davis

    By Jeff Hudson | From Page: A1 | Gallery

    State races test one-party rule

    By New York Times News Service | From Page: A2

     
    Couple killed in Yolo County crash

    By Lauren Keene | From Page: A2

     
    Same-party races challenge incumbents

    By The Associated Press | From Page: A2

     
    Indians celebrate Diwali with gala on Sunday

    By Special to The Enterprise | From Page: A3

    Rairdan dinged for late report

    By Jeff Hudson | From Page: A3

     
    Veterans will tailgate at ‘Salute to Heroes’ game

    By Enterprise staff | From Page: A3

    Wolk hailed for environmental votes

    By Enterprise staff | From Page: A3

     
    Yamada honored for leadership on aging issues

    By Enterprise staff | From Page: A3

    Embroidery group meets at mall

    By Enterprise staff | From Page: A3

     
    Bones for Life classes offered

    By Enterprise staff | From Page: A4

    Bet Haverim will hear Israel update

    By Special to The Enterprise | From Page: A4

     
    Local artisans featured at holiday craft fair

    By Enterprise staff | From Page: A4

    Got bikes? Donate ‘em!

    By Enterprise staff | From Page: A4

     
    Kids walk for friends at Birch Lane

    By Special to The Enterprise | From Page: A4

    Explorit: Creep out with some spooky science

    By Lisa Justice | From Page: A4

     
    Shambhala offers Tai Chi class

    By Special to The Enterprise | From Page: A4

    Enjoy wine, music and art at Sunday fundraiser for DHS choir

    By Anne Ternus-Bellamy | From Page: A9

     
    .

    Forum

    New-school cheating on the smartphone

    By Creators Syndicate | From Page: B5

     
    My choices on Tuesday

    By Letters to the Editor | From Page: A10

     
    Garamendi, Dodd get my votes

    By Letters to the Editor | From Page: A10

    Tom Meyer cartoon

    By Debbie Davis | From Page: A10

     
    High hopes for Sunder

    By Letters to the Editor | From Page: A10

    Public service is in her heart

    By Letters to the Editor | From Page: A10

     
    A calm, thoughtful voice

    By Letters to the Editor | From Page: A10

    Sunder is a perfect fit

    By Letters to the Editor | From Page: A10

     
    Best predictor is past behavior

    By Letters to the Editor | From Page: A10

    Vote for students, with Tuck

    By Letters to the Editor | From Page: A10

     
    .

    Sports

    DHS plays undefeated Pacers Friday night

    By Enterprise staff | From Page: B1

     
    Blue Devil girls net an easy win at Grant

    By Enterprise staff | From Page: B1 | Gallery

    Aggie offense A-OK; now what about defense?

    By Bruce Gallaudet | From Page: B1 | Gallery

     
    In Davis, rugby is as American as apple pie

    By Bruce Gallaudet | From Page: B1

     
     
    Niemi’s 43 saves aren’t enough in loss to Wild

    By The Associated Press | From Page: B8 | Gallery

    .

    Features

    .

    Arts

     
    Calling all artists for upcoming show

    By Enterprise staff | From Page: A11

    ‘Birdman': A dark comedy that soars

    By Derrick Bang | From Page: A11

     
    DHS Madrigals host singing workshop

    By Enterprise staff | From Page: A12

     
    Marcia Ball to play at The Palms

    By Enterprise staff | From Page: A12 | Gallery

     
    .

    Business

    Big, capable luxury defines Yukon

    By Ann M. Job | From Page: A5 | Gallery

     
    .

    Obituaries

    Joseph Francis Gray

    By Special to The Enterprise | From Page: A4

     
    .

    Comics

    Comics: Friday, October 31, 2014

    By Creator | From Page: B6

     
    .

    Real Estate Review

    Featured Listing

    By Special to The Enterprise | From Page: RER1

    Professional Services Directory

    By Special to The Enterprise | From Page: RER2

    Lyon Real Estate

    By Special to The Enterprise | From Page: RER3

    RE/Max Gold

    By Special to The Enterprise | From Page: RER4

    Kim Eichorn

    By Special to The Enterprise | From Page: RER5

    Yolo FCU

    By Special to The Enterprise | From Page: RER6

    Juan Ramirez

    By Special to The Enterprise | From Page: RER6

    Susan von Geldern

    By Special to The Enterprise | From Page: RER6

    Team Traverso

    By Special to The Enterprise | From Page: RER6

    Tracy Harris

    By Special to The Enterprise | From Page: RER7

    Susan von Geldern

    By Special to The Enterprise | From Page: RER7

    Wells Fargo Home Mortgage

    By Special to The Enterprise | From Page: RER8

    Julie Leonard

    By Special to The Enterprise | From Page: RER8

    Joe Kaplan

    By Special to The Enterprise | From Page: RER9

    Melrina A Maggiora

    By Special to The Enterprise | From Page: RER9

    Coldwell Banker

    By Special to The Enterprise | From Page: RER10

    Leslie Blevins

    By Special to The Enterprise | From Page: RER12

    Julie Partain

    By Special to The Enterprise | From Page: RER12

    Robin Garland

    By Special to The Enterprise | From Page: RER13

    Jamie Madison

    By Special to The Enterprise | From Page: RER13

    Diane Lardelli

    By Special to The Enterprise | From Page: RER13

    Karen Waggoner

    By Special to The Enterprise | From Page: RER14

    Jamie Madison & Associates

    By Special to The Enterprise | From Page: RER14

    Lisa Haass

    By Special to The Enterprise | From Page: RER14

    Ciana Wallace

    By Special to The Enterprise | From Page: RER15

    Travis Credit Union

    By Special to The Enterprise | From Page: RER16

    Malek Baroody

    By Special to The Enterprise | From Page: RER17

    Marcelo Campos

    By Special to The Enterprise | From Page: RER18

    F1rst Street Real Estate

    By Special to The Enterprise | From Page: RER20